Ken Song, RayzeBio CEO

Ra­dio­phar­ma­ceu­ti­cals start­up Rayze­Bio sub­mits IPO pitch, fore­shad­ow­ing ex­pect­ed post-La­bor Day bump in biotech list­ings

A Phase III-stage ra­dio­phar­ma­ceu­ti­cals biotech has filed to go pub­lic a lit­tle over a week be­fore bankers and in­dus­try watch­ers ex­pect a slight post-La­bor Day bump in biotech IPO pitch­es.

Af­ter hav­ing raised $418 mil­lion pri­vate­ly, the San Diego start­up Rayze­Bio hopes to gain a spot on the Nas­daq and trade as “RYZB,” per an S-1 fil­ing from Thurs­day evening.

Rayze­Bio is like­ly one of a few drug de­vel­op­ers that will go pub­lic be­fore year’s end; Jor­dan Saxe, Nas­daq’s head of health­care list­ings, told End­points News last month that the ex­change an­tic­i­pates an­oth­er five to 10 be­fore New Year’s. Biotechs will look to pounce on any win­dow they can get in this mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.